Zobrazeno 91 - 100
of 1 154
pro vyhledávání: '"35"'
Autor:
A. Snyder, Daniel Shao Weng Tan, Roy S. Herbst, Lawrence Fong, Martin Gutierrez, Enriqueta Felip, Matthew A. Gubens, Andrea D. Basso, Charu Aggarwal, Edward B. Garon, Hua Ma, Jianda Yuan, Joanne Wing Yan Chiu, Jong Seok Lee, James Chih-Hsin Yang, Matthew D. Hellmann
Publikováno v:
Cancer Research. 79:CT227-CT227
Background: Immune checkpoint-based therapy has revolutionized the care of patients with NSCLC. Pembrolizumab-based combination therapy aims to improve clinical outcomes over pembrolizumab monotherapy. Identification of biomarkers associated with imp
Publikováno v:
Cancer Research. 79:3316-3316
Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome, caused primarily by germline pathogenic TP53 variants and associated with a very high lifetime cancer risk which reaches approximately 100% by age 60 years. Individua
Autor:
Arianna Damiani, Jason Law, Michael Frid, Lita De Leon, Maria Vilenchik, Olga Potapova, Menelik Duey, Alexandra Kuznetsova
Publikováno v:
Cancer Research. 79:3038-3038
Majority of tumors consist of two populations of cancer cells: actively proliferating and those in the reversible dormant or quiescent state, which contribute to the resistance of human tumors to chemotherapies. Conventional chemotherapeutic agents h
Autor:
Lori Steelman, Elia Aguado-Fraile, Liewen Jiang, Bin Fan, Sung Choe, Camelia Gliser, Susan Pandya, Kha Le, Bin Wu, Maeve A. Lowery
Publikováno v:
Cancer Research. 79:2275-2275
Somatic mutations in the isocitrate dehydrogenase 1 (IDH1) gene are detected in 13-15% of cholangiocarcinoma (CC) cases overall and up to ~25% of intrahepatic CC cases. Ivosidenib (AG-120) is a first-in-class, oral, potent, reversible, targeted inhib
Autor:
Sho Saeki, Akinobu Hamada, Toshiyuki Harada, Satoshi Igawa, Hiroyuki Minemura, Ryo Ko, Shigehiro Yagishita, Takamasa Hotta, Kageaki Watanabe, Satoshi Oizumi, Yuka Fujita, Hidenori Mizugaki, Taichi Takashina
Publikováno v:
Cancer Research. 79:3998-3998
Background: Although reports on the use of gefitinib and erlotinib in elderly patients are occasionally found, reports on afatinib are rare. According to the analysis of 54 Japanese patients in the LUX-Lung3 study, an afatinib dose reduction from 40
Autor:
Adam E. Flanders, Lyndon Kim, Mark T. Curtis, Emily K. Bongiorno, Maria Werner-Wasik, Rhonda B. Kean, Samantha Garcia, Kara Pigott, Sami Sauma, D. Craig Hooper, Kofi-Buaku Atsina, Kevin Judy, Sanjana Govindarajan, Charles B. Scott, David W. Andrews, Nina L. Martinez, Lawrence C. Kenyon, Wenyin Shi, Larry Harshyne, Kiran Talekar, Mikhail Prosniak
Publikováno v:
Cancer Research. 79:CT038-CT038
Background: We evaluated an autologous cell vaccine, a combination of GBM tumor cells and an antisense molecule against insulin-like growth factor type 1 receptor DNA/mRNA (IGF-1R AS ODN), in adults with newly diagnosed GBM (NCT02507583). Methods: Tu
Publikováno v:
Cancer Research. 73:P2-15
Background: Recurrence rates have declined since AT was added to chemotherapy (chx) for her2+ early breast cancer (BC). This has led to under-representation of patients (pts) relapsing after AT in M1 anti-her2 therapy trials. Trastuzumab was introduc
Autor:
Maureen E. Trudeau, L.B. Pritzker, Baoqing Guo, Amadeo M. Parissenti, X. Wang, Mu Zhu, Kenneth P.H. Pritzker
Publikováno v:
Cancer Research. 73:P1-08
Background: We recently reported that epirubicin/docetaxel treatment of locally advanced breast cancer patients in the MA.22 clinical trial reduced tumor RNA integrity and that low mid-treatment tumor RNA integrity was associated with a pathologic co
Autor:
Kevin Kalinsky, DL Hershman, MM Maurer, B Taback, Katherine D. Crew, Sheldon Feldman, Hanina Hibshoosh, S Refice, Tian Zheng, Tao Su
Publikováno v:
Cancer Research. 73:P4-15
Background: Laboratory and population studies demonstrate that metformin offers a beneficial breast cancer (BC) effect through reduction of serum insulin levels and changes in cellular protein synthesis and growth, such as AMPK pathway signaling. In
Autor:
Tamas Hickish, E. A. Perez, Linda T. Vahdat, Ahmad Awada, David Cameron, Neil L. Spector, David A. Proia, Henry L. Gomez, Angel Rodriguez, John K. Erban, V. Vukovic, I Yalcin, Luis Fein, Anthony Kong, S Mansoor, A Giovanne, R Bradley, Iman El-Hariry, Karen McAdam, J-L Canon, J. Cortes, Iain R. Macpherson, Mano
Publikováno v:
Cancer Research. 73:P2-16
Background: Hsp90 is a molecular chaperone protein required for the stabilization and activation of many proteins, referred to as Hsp90 ‘clients’, such as HER2, HIF1-a, EGFR, ER, PI3K, AKT, P53 and VEGFR. The drug candidate, ganetespib is a novel